(Press-News.org) HOUSTON ― The University of Texas MD Anderson Cancer Center today announced Kerin Adelson, M.D., as the institution’s chief quality and value officer. An accomplished clinician and researcher with extensive leadership experience in delivering high-quality and value-based cancer care, Adelson will begin her role March 20. She also will hold a faculty appointment in Breast Medical Oncology.
As chief quality and value officer, Adelson will partner with Chief Administrative Quality Officer José Rivera to lead MD Anderson’s medical practice quality improvement efforts and value-based care initiatives in support of the institution’s Strategy. She also will be responsible for guiding initiatives aimed at optimizing the cost and quality of patient care and demonstrating value to prospective insurers, with a goal of implementing innovative reimbursement models that increase access to cancer care services here and across the MD Anderson Cancer Network®.
Adelson also will provide strategic oversight and support for the Institute for Cancer Care Innovation, patient care informatics medical directors, and teams working in clinical effectiveness, tumor registry and Cancer Network quality improvement. She will collaborate with Rivera to provide leadership for the Quality Assessment and Performance Improvement (QAPI) council and with Chief Patient Safety Officer Carmen Gonzalez, M.D., to provide support for MD Anderson’s Divisional Patient Safety Quality Officers.
“As we continue to advance our mission to end cancer, we are committed to improving the lives of our patients and their families. Central to that is our strategic focus on high-touch, high-value cancer care,” said Peter WT Pisters, M.D., president of MD Anderson. “Dr. Adelson brings tremendous experience and insightful leadership that will help us to advance our efforts in this space and ensure optimal, value-based care for all patients.”
Since 2014, Adelson has served as chief quality officer and deputy chief medical officer at Yale Cancer Center and Smilow Cancer Hospital in New Haven, Connecticut. In her role, she collaborated with physician, nursing and finance leadership to implement quality and safety programs and to design new programs in care management, apply clinical pathways to ensure use of evidence-based therapies, and introduce co-managed hospitalist services to improve the length of patient stays.
Her experience in executive leadership has included overseeing payor relationships for oncology services, multidisciplinary centers for excellence and direct-to-employer strategies. She led Yale’s participation in the Oncology Care Model, a value-based payment model from the Centers for Medicare and Medicaid Services (CMS) focused on delivering highly coordinated oncology care through better patient navigation, treatment therapies aligned with nationally recognized clinical guidelines, and the use of data to drive continuous quality improvement.
In addition, she oversaw Yale’s participation in both Anthem’s Oncology Medical Home program as well as the American Society of Clinical Oncology’s Patient-Centered Cancer Care Certification pilot – an ambitious program designed to improve oncology care delivery via rigorous standards in advance care planning, symptom management, goal-concordant care communication, care coordination and clinical treatment pathways.
“As one of the world’s most respected cancer centers, MD Anderson has an unparalleled opportunity to impact cancer care delivery on a national and international level,” Adelson said. “I am tremendously excited to join this stellar community and partner with world-renowned clinicians and scientists to advance MD Anderson’s strategic vision and mission.”
Adelson is a practicing medical oncologist and clinical researcher specializing in breast cancer, and she has been an investigator on multiple clinical trials for early-stage and metastatic disease. She also is an accomplished researcher in health services and clinical care delivery, with published research and insights on end-of-life care, new models of value-based care and clinical care redesign.
Adelson earned her medical degree at Yale School of Medicine and completed her residency and fellowship in New York at Mount Sinai School of Medicine and Columbia University College of Physicians and Surgeons, respectively. She joined Yale Cancer Center and Smilow Cancer Hospital in 2014 and was promoted to associate professor in 2017. She also earned a master’s degree in Health Care Delivery Science from Dartmouth’s Tuck School of Business and Geisel School of Medicine.
She is a current member of the National Comprehensive Cancer Network’s Policy Committee and a former chair of the American Society of Clinical Oncology Quality Council. In addition, she’s a sought-after national speaker on cancer care quality, cost of care and shared decision-making in cancer treatment – including the value of establishing goal-concordant care with patients.
“Dr. Adelson is exceptionally well-suited to this important leadership role, and I am confident her experience, strategic vision and alignment with our core values will serve MD Anderson, our patients and our Cancer Network partners well,” said Welela Tereffe, M.D., chief medical executive. “I look forward to collaborating with her and other leaders to advance impactful and innovative quality, safety and value-based initiatives that consider the total patient experience.”
- 30 -
Micron-sized "bow ties," self-assembled from nanoparticles, form a variety of different curling shapes that can be precisely controlled, a research team led by the University of Michigan has shown.
The development opens the way for easily producing materials that interact with twisted light, providing new tools for machine vision and producing medicines.
While biology is full of twisted structures like DNA, known as chiral structures, the degree of twist is locked in—trying to change it breaks the structure. Now, researchers can engineer the degree of twist.
Such materials ...
BOSTON – A new targeted drug has not only sparked remissions in patients with a common form of leukemia but also induced the cancer cells to reveal one of their schemes for resisting the drug, investigators at Dana-Farber Cancer Institute and other research centers report in a new pair of studies in the journal Nature.
One of the papers presents results of a clinical trial in which approximately 40% of patients with acute leukemia subtypes had a complete response – a disappearance of all signs of cancer – to treatment with the drug revumenib. The other paper uncovers a molecular countermove by which leukemia cells come to sidestep the drug and reassert their growth.
Breaking a longstanding impasse in our understanding of olfaction, scientists at UC San Francisco (UCSF) have created the first molecular-level, 3D picture of how an odor molecule activates a human odorant receptor, a crucial step in deciphering the sense of smell.
The findings, appearing online March 15, 2023, in Nature, are poised to reignite interest in the science of smell with implications for fragrances, food science, and beyond. Odorant receptors - proteins that bind odor molecules on the surface of olfactory cells - make up half of the largest, most diverse family of receptors in our bodies; A deeper understanding of them paves the way for ...
Scientists have long known that mitochondria, the "powerhouses" of cells, play a crucial role in the metabolism and energy production of cancer cells. However, until now, little was known about the relationship between the structural organization of mitochondrial networks and their functional bioenergetic activity at the level of whole tumors.
In a new study, published in Nature, researchers from the UCLA Jonsson Comprehensive Cancer Center used positron emission tomography (PET) in combination ...
Francis Crick Institute press release
Under strict embargo: 16:00hrs GMT Wednesday, March 15, 2023
Animals / Cells
Artificial Sweetener could dampen immune response to disease in mice
Scientists at the Francis Crick Institute have found that high consumption of a common artificial sweetener, sucralose, lowers activation of T-cells, an important component of the immune system, in mice.
If found to have similar effects in humans, one day it could be used therapeutically to help dampen T-cell responses. For example, in patients with autoimmune diseases who ...
A pioneering global study has found deforestation and forests lost or damaged due to human and environmental change, such as fire and logging, are fast outstripping current rates of forest regrowth.
Tropical forests are vital ecosystems in the fight against both climate and ecological emergencies. The research, published today in Nature and led by the University of Bristol, highlights the carbon storage potential and the current limits of forest regrowth to addressing such crises.
The findings showed degraded forests recovering from human disturbances, and secondary forests regrowing ...
Researchers from The University of Texas MD Anderson Cancer Center showed that inhibiting menin with revumenib, previously known as SNDX-5613, yielded encouraging responses for advanced acute leukemias with KMT2A rearrangements or mutant NPM1. Findings from the Phase I AUGMENT-101 trial were published today in Nature.
The overall response rate among 60 patients was 53%, and the rate of complete remission or complete remission with partial hematologic recovery was 30%, with 78% of patients achieving clearance of measurable residual disease. Responses were seen across multiple dose ...
Researchers at Cummings School of Veterinary Medicine at Tufts University found that an outbreak of highly pathogenic avian influenza (HPAI) was associated with the deaths of more than 330 New England harbor and gray seals along the North Atlantic coast in June and July 2022, and the outbreak was connected to a wave of avian influenza in birds in the region.
The study was published on March 15 in the journal Emerging Infectious Disease.
HPAI is more commonly known as bird flu, and the H5N1 strain has been responsible for about 60 million poultry ...
In a step forward for genetic engineering and synthetic biology, researchers have modified a strain of Escherichia coli bacteria to be immune to natural viral infections while also minimizing the potential for the bacteria or their modified genes to escape into the wild.
The work promises to reduce the threats of viral contamination when harnessing bacteria to produce medicines such as insulin as well as other useful substances, such as biofuels. Currently, viruses that infect vats of bacteria can halt production, compromise ...
Scientists at EPFL and IBM have developed a new type of laser that could have a significant impact on optical ranging technology. The laser is based on a material called lithium niobate, often used in the field of optical modulators, which controls the frequency or intensity of light that is transmitted through a device.
Lithium niobate is particularly useful because it can handle a lot of optical power and has a high “Pockels coefficient”, which means that it can change its optical properties when an electric field is applied to it.
The researchers achieved their breakthrough by combining ...